PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch

Overview

Understanding Delays in the Diagnosis of Pulmonary Arterial Hypertension and Rare Diseases in Brazil: A Multicenter Observational Study \--- Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease that affects the arteries of the lungs and the right side of the heart. Early diagnosis is essential to initiate appropriate treatment and improve patient outcomes. However, worldwide studies show that there is often a significant delay between the onset of symptoms and the final diagnosis. This delay may lead to disease progression and worse survival. This multicenter observational study aims to understand the time from the first symptoms to the diagnosis of PAH and other rare diseases across several Brazilian reference centers. By analyzing medical records and patient journeys, the investigators intends to identify factors contributing to delayed diagnosis and potential opportunities for earlier detection. The study includes adult patients diagnosed with PAH or other selected rare diseases within the last five years. The investigators will analyze time to diagnosis, number and type of physicians consulted, tests performed, and possible misdiagnoses. Our goal is to support the development of strategies that reduce diagnostic delay and improve access to specialized care for people living with rare diseases. This study does not involve any intervention and poses no additional risk to participants, as it is based solely on retrospective data from medical records.

Background and Rationale: Pulmonary arterial hypertension (PAH) is a rare condition characterized by progressive elevation of pulmonary artery pressure, leading to right ventricular dysfunction and death if untreated. Despite advances in therapy and increasing awareness, several studies have consistently shown substantial diagnostic delays. For example, in the Australian DELAY study, the mean time from symptom onset to diagnosis of idiopathic PAH was nearly 4 years (47 ± 34 months), and patients typically visited multiple general practitioners and specialists before referral to a PAH center. In Latin America, similar findings were reported, with patients waiting an average of 1.6 years from first symptoms to diagnosis and over 50% receiving a misdiagnosis, such as asthma or heart failure, prior to PAH confirmation . Delays are not limited to PAH. For many rare diseases, such as primary immunodeficiencies, sarcoidosis, and myositis, patients often experience a prolonged and complex journey to diagnosis. A recent qualitative study in Australia highlighted delays ranging from months to decades, with barriers including misattribution of symptoms, clinician bias, and fragmentation of care. In Brazil, data on time to diagnosis for PAH and other rare diseases are limited. Understanding the diagnostic trajectory in the local context is critical to guide health policies and professional education. Objectives: The primary objective of this study is to characterize the time from symptom onset to confirmed diagnosis in patients with PAH and other selected rare diseases, and to identify common barriers and facilitators to diagnosis. Specific Aims: * Estimate the average and median time from first symptom to diagnosis. * Quantify the number and types of healthcare professionals consulted before diagnosis. * Identify common misdiagnoses prior to the final diagnosis. * Evaluate use and timing of diagnostic tools (e.g., echocardiogram, right heart catheterization, imaging). * Compare diagnostic delays across regions and reference centers. * Identify associations between patient characteristics (age, sex, location) and time to diagnosis. Study Design: This is a retrospective, multicenter, observational study involving data collection from medical records of patients diagnosed with PAH or other rare diseases in participating reference centers across Brazil. The study will include patients diagnosed in the last five years and will not involve any direct patient contact or intervention. Participating Centers: Tertiary hospitals with dedicated outpatient clinics for pulmonary hypertension and rare diseases in major Brazilian cities, including São Paulo, Rio de Janeiro, Recife, Fortaleza, Belém, Vitória, and Curitiba. Eligibility Criteria: \- Adult patients (≥18 years) diagnosed with PAH (Group 1 PH) or other selected rare diseases. Confirmed diagnosis based on international or national diagnostic criteria. \- Sufficient medical record data available to estimate time from first symptom to diagnosis. Data Collection and Analysis: Data will be extracted from patient records using a standardized case report form. Key variables include: * Date of symptom onset (as described by patient or noted in clinical notes) * Date of first medical consultation * Number of general practitioner and specialist visits before diagnosis * Diagnostic tests performed and their dates * Initial diagnoses prior to final diagnosis * Date of confirmed diagnosis (e.g., date of right heart catheterization in PAH) * Demographic information (age, sex, region, referral source) Quantitative analyses will be performed to describe central tendencies (mean, median) and dispersion (standard deviation, interquartile range) of time to diagnosis. Associations between delay and clinical variables will be explored using regression models. Expected Outcomes and Relevance: The investigators anticipate confirming that diagnostic delay is significant in the Brazilian context, similar to international studies. Identifying the stages at which delay occurs (e.g., late presentation, misdiagnosis, referral lag) will allow the design of targeted interventions. * This study will provide baseline data to support future initiatives such as: * Educational programs for primary care providers * Diagnostic algorithms or checklists * Patient education campaigns * Policy advocacy for improved rare disease care networks Ethical Considerations: This is a non-interventional study involving retrospective review of anonymized patient data. Approval will be obtained from local institutional review boards. No patient consent is required due to the retrospective design. "This is a mixed observational study including both retrospective and prospective data. Retrospective data will be collected from medical records of patients diagnosed within the past 5 years. In addition, prospective data may be collected during follow-up visits or complementary assessments to complete the diagnostic journey profile, when needed."